Neurocrine Biosciences to Present at Upcoming Healthcare Conferences

SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Neurocrine Biosciences management will present at the following investor conferences:

    --  Kevin Gorman, Chief Executive Officer, and Kyle Gano, Chief Business
        Development and Strategy Officer, will present at the Stifel 2020
        Virtual Healthcare Conference at 11:20 a.m. Eastern Time on Monday,
        November 16, 2020.
    --  Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief
        Financial Officer, will present at the Jefferies Virtual London
        Healthcare Conference at 2:40 p.m. Greenwich Mean Time (9:40 a.m.
        Eastern Time) on Tuesday, November 17, 2020.

The live presentations will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com. A replay of the presentations will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, Neurocrine Biosciences has specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)

View original content to download multimedia:http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-upcoming-healthcare-conferences-301168288.html

SOURCE Neurocrine Biosciences, Inc.